畜牧兽医学报 ›› 2021, Vol. 52 ›› Issue (6): 1689-1699.doi: 10.11843/j.issn.0366-6964.2021.06.023

• 预防兽医 • 上一篇    下一篇

猪丹毒丝菌CbpB蛋白对小鼠的免疫效果分析

刘君雯1, 吴琼娟1, 邢刚2, 占松鹤3, 魏建忠1, 孙裴1, 刘雪兰1, 李郁1*   

  1. 1. 安徽农业大学动物科技学院, 合肥 230036;
    2. 马鞍山史记动物健康管理有限公司, 马鞍山 238251;
    3. 安徽省动物疫病预防与控制中心, 合肥 230091
  • 收稿日期:2020-06-29 出版日期:2021-06-23 发布日期:2021-06-22
  • 通讯作者: 李郁,主要从事动物传染病学研究,E-mail:liyouer@163.com
  • 作者简介:刘君雯(1997-),女,安徽全椒人,硕士生,主要从事动物传染病学研究,E-mail:840491505@qq.com;吴琼娟(1994-),女,安徽池州人,硕士生,主要从事动物传染病学研究,E-mail:531092426@qq.com。刘君雯和吴琼娟为同等贡献作者
  • 基金资助:
    国家星火计划重点项目(2014GA710002);安徽省重点研究与开发计划(面上攻关)项目(201904a06020013);安徽省长三角联合科技攻关项目(1101c0603065);安徽省生猪产业体系基金项目[皖农科(2016)84号]

Immunogenicity Analysis and Protective Effects of CbpB Protein of Erysipelothrix rhusiopathiae in Mice

LIU Junwen1, WU Qiongjuan1, XING Gang2, ZHAN Songhe3, WEI Jianzhong1, SUN Pei1, LIU Xuelan1, LI Yu1*   

  1. 1. College of Animal Science and Technology, Anhui Agricultural University, Heifei 230036, China;
    2. Maanshan Shiji Animal Health Management Co., Ltd, Maanshan 238251, China;
    3. Anhui Animal Disease Prevention and Control Center, Hefei 230091, China
  • Received:2020-06-29 Online:2021-06-23 Published:2021-06-22

摘要: 探究猪丹毒丝菌(ER)CbpB蛋白的免疫原性和保护作用,为深入研制ER基因工程亚单位疫苗提供新的思路和技术储备。以表达的ER重组蛋白CbpB、SpaA、CbpB+SpaA以及ER灭活全菌体(V-AEr21)、商品化弱毒疫苗、商品化灭活疫苗分别免疫小鼠。利用间接ELISA检测小鼠血清中IgG抗体,血清杀菌试验测定功能性抗体水平,攻毒试验测定免疫保护率,组织荷菌数试验测定ER定植情况,并采集小鼠组织脏器(脾、肺、肝、肾)制备切片,观察病理变化。结果显示:与免疫原性最优的商品化弱毒疫苗相比,CbpB和SpaA虽产生的IgG抗体均仅为1∶6 400,但血清杀菌效果强;对小鼠的免疫攻毒保护率与商品化弱毒疫苗相同,均为100%,且在脾、肺、肝、肾组织中均无细菌定植,病理组织学观察与空白对照无明显区别。CbpB重组蛋白具有良好的免疫原性和保护作用,能刺激机体产生体液免疫和细胞免疫,可以作为猪丹毒基因工程亚单位疫苗的候选抗原。

关键词: 猪丹毒丝菌, CbpB蛋白, 小鼠, 免疫原性, 免疫保护力

Abstract: This study aimed to explore the immunogenicity and protective effects of CbpB protein of Erysipelothrix rhusiopathiae, and to provide new ideas and technical reserves for the further development of ER genetic engineering subunit vaccine. Mice were immunized with the expressed ER recombinant proteins CbpB, SpaA, CbpB+SpaA, ER inactivated whole cell (V-AEr21), commercial attenuated vaccine, and commercial inactivated vaccine, respectively. Indirect ELISA was used to detect the level of IgG antibodies. The challenge test was selected to determine the immune protection rate. Tissue bacteria count test was conducted to determine ER colonization. Mouse tissue organs (spleen, lung, liver, and kidney) were collected to prepare slices and observe pathological changes. Compared with the commercial attenuated vaccine with the strongest immunogenicity, the IgG antibody produced by CbpB and SpaA was only 1:6 400, but the bactericidal efficacy of serum was high. The immune challenge protection rate of mice was the same as that of commercial attenuated vaccine, which was 100%, and there was no bacterial colonization in spleen, lung, liver and kidney, and there was no significant difference between histopathological observation and blank control. There was no difference between CbpB and SpaA. CbpB recombinant protein has good immunogenicity and protective efficacy, can stimulate the body to produce humoral immunity and cellular immunity, and can be used as a candidate antigen for swine erysipelas genetic engineering subunit vaccine.

Key words: Erysipelothrix rhusiopathiae, CbpB protein, mouse, immunogenicity, immune protection

中图分类号: